JP Patent

JP2003525201A — 新規な置換トリアゾール化合物

Assigned to SmithKline Beecham Corp · Expires 2003-08-26 · 23y expired

What this patent protects

(57)【要約】ＣＳＢＰ／ｐ３８キナーゼ阻害剤として治療に有用な新規な置換トリアゾール化合物および組成物。

USPTO Abstract

(57)【要約】ＣＳＢＰ／ｐ３８キナーゼ阻害剤として治療に有用な新規な置換トリアゾール化合物および組成物。

Drugs covered by this patent

nintedanib-esylate (NINTEDANIB ESYLATE)

Patent Metadata

Patent number: JP2003525201A
Jurisdiction: JP
Classification: —
Expires: 2003-08-26
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.